Knockdown of ChREBP ameliorates retinal microvascular endothelial cell injury and angiogenic responses in diabetic retinopathy
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2023.149389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Yao Sui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Diabetic Retinopathy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Hebei Medical University, Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
PURPOSE: To examine whether and how carbohydrate response element-binding protein (ChREBP) plays a role in diabetic retinopathy. METHODS: Western blotting was used to detect ChREBP expression and location following high glucose stimulation of Human Retinal Microvascular Endothelial Cells (HRMECs). Flow cytometry, TUNEL staining, and western blotting were used to evaluate apoptosis following ChREBP siRNA silencing. Cell scratch, transwell migration, and tube formation assays were used to determine cell migration and angiogenesis. Diabetic models for wild-type (WT) and ChREBP knockout (ChKO) mice were developed. Retinas of WT and ChKO animals were cultivated in vitro with vascular endothelial growth factor + high glucose to assess neovascular development. RESULTS: ChREBP gene knockdown inhibited thioredoxin-interacting protein and NOD-like receptor family pyrin domain containing protein 3 expression in HRMECs, which was caused by high glucose stimulation, reduced apoptosis, hindered migration, and tube formation, and repressed AKT/mTOR signaling pathway activation. Compared with WT mice, ChKO mice showed suppressed high glucose-induced alterations in retinal structure, alleviated retinal vascular leakage, and reduced retinal neovascularization. CONCLUSIONS: ChREBP deficiency decreased high glucose-induced apoptosis, migration, and tube formation in HRMECs as well as structural and angiogenic responses in the mouse retina; thus, it is a potential therapeutic target for diabetic retinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Pathology, Hebei Medical University, Key Laboratory of Kidney Diseases of Hebei Province, Shijiazhuang, China; Center of Metabolic Diseases and Cancer research, Institute of Medical and Health Science, Heb…
- Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: majingxue99@126.com.
- Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: duanjialiang@hebmu.edu.cn.
Förderung
- Hebei Medical University
- Natural Science Foundation of Hebei Province
Zitieren
APA
Sui, Y., Du, C., Wang, M., Liu, X., Chai, Q., Liang, S., Ma, J., & Duan, J. (2024). Knockdown of ChREBP ameliorates retinal microvascular endothelial cell injury and angiogenic responses in diabetic retinopathy. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149389
Vancouver
Sui Y, Du C, Wang M, Liu X, Chai Q, Liang S, et al. Knockdown of ChREBP ameliorates retinal microvascular endothelial cell injury and angiogenic responses in diabetic retinopathy. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2023.149389
BibTeX
@article{Sui2024,
author = {Sui, Yao and Du, Chunyang and Wang, Ming and Liu, Xiaoli and Chai, Qiannan and Liang, Shuang and Ma, Jingxue and Duan, Jialiang},
title = {Knockdown of ChREBP ameliorates retinal microvascular endothelial cell injury and angiogenic responses in diabetic retinopathy},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2023.149389}
}
EUVIMED